Generate BiomedicinesGENB +2.18%6 Market Cap is $2,167.74 Mil as of Jun. 29, 2026. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 1,428 Biotechnology companies, Generate Biomedicines ranks better than 88.8% on this metric.
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Generate Biomedicines's Enterprise Value for Today is $1,709.43 Mil.
Generate Biomedicines (NAS:GENB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Generate Biomedicines Market Cap Chart
Generate Biomedicines Annual Data
Trend
Dec24
Dec25
Market Cap
0.00
0.00
Generate Biomedicines Semi-Annual Data
Dec24
Dec25
Market Cap
0.00
0.00
GENB vs PVLA, SLBT, NKTR: Market Cap Comparison
For the Biotechnology subindustry, Generate Biomedicines's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Generate Biomedicines Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Generate Biomedicines's Market Cap distribution charts can be found below:
* The bar in red indicates where Generate Biomedicines's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Generate Biomedicines's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Generate Biomedicines (GENB) has a Market Cap of $2,167.74 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Generate Biomedicines and its competitors. According to the industry distribution chart, Generate Biomedicines ranks #160 out of 1428 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Generate Biomedicines' Market Cap too high?
Generate Biomedicines' current Market Cap is $2,167.74 Mil. The Biotechnology industry median Market Cap is 114.03. Generate Biomedicines' value of $2,167.74 Mil is 1801% above this industry median. Based on the distribution chart, Generate Biomedicines ranks #160 out of 1428 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' Market Cap compare to PVLA and SLBT?
According to the Biotechnology industry distribution chart, Generate Biomedicines ranks #160 out of 1428 companies for Market Cap. This places Generate Biomedicines in the top 11% of its industry — outperforming the majority of peers. The industry median Market Cap is 114.03. Generate Biomedicines' value of $2,167.74 Mil is 1801% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Generate Biomedicines's current Market Cap of $2,167.74 Mil is 1801% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Generate Biomedicines and its competitors. For the Biotechnology industry, the median Market Cap is 114.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Generate Biomedicines's current Market Cap is $2,167.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current Market Cap of $2,167.74 Mil. The current Market Cap is $2,167.74 Mil and 1801% above the Biotechnology industry median of 114.03. Generate Biomedicines' overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current Market Cap is $2,167.74 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score
Get the complete analysis for GENB
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GENB has been successfully added to your 